Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy.
Journal: International journal of molecular sciences
Published: December 23, 2025
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.
Journal: British journal of cancer
Published: July 06, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 24, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.
Journal: NPJ precision oncology
Published: June 17, 2025
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
Journal: Future oncology (London, England)
Published: December 14, 2023
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
Journal: Nature communications
Published: September 18, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 10, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Journal: Future oncology (London, England)
Published: May 22, 2023
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Journal: JCO precision oncology
Published: August 11, 2022
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 17, 2022
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.
Journal: Frontiers in oncology
Published: December 06, 2020
ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 01, 2018
Last Updated: 09/26/2026